Abstract

Classical swine fever (CSF) is a highly contagious swine disease caused by classical swine fever virus (CSFV). Previously, we demonstrated that rAdV-SFV-E2, an adenovirus-delivered, Semliki Forest virus replicon-vectored marker vaccine against CSF, is able to protect pigs against lethal CSFV challenge. From an economical point of view, it will be beneficial to reduce the minimum effective dose of the vaccine. This study was designed to test the adjuvant effects of Salmonella enteritidis-derived bacterial ghosts (BG) to enhance the protective immunity of rAdV-SFV-E2 in pigs. Groups of 5-week-old pigs (n = 4) were immunized intramuscularly twice with 105 median tissue culture infective doses (TCID50) rAdV-SFV-E2 combined with 1010 colony forming units (CFU) BG, 106 or 105 TCID50 rAdV-SFV-E2 alone or 1010 CFU BG alone at an interval of 3 weeks, and challenged with the highly virulent CSFV Shimen strain at 1 week post-booster immunization. The results show that the pigs inoculated with 105 TCID50 rAdV-SFV-E2 plus BG or 106 TCID50 rAdV-SFV-E2 alone were completely protected from lethal CSFV challenge, in contrast with the pigs vaccinated with 105 TCID50 rAdV-SFV-E2 or BG alone, which displayed partial or no protection following virulent challenge. The data indicate that BG are a promising adjuvant to enhance the efficacy of rAdV-SFV-E2 and possibly other vaccines.

Highlights

  • Classical swine fever (CSF) is one of the most contagious diseases and characterized by high fever and high mortality, resulting in huge economic losses to the pig industry [1]

  • We developed a marker CSF vaccine rAdV-SFV-E2 based on human adenovirus type 5 (HAdV-5)/alphavirus replicon chimeric vector

  • The results show that pigs injected with TCID50 rAdV-SFV-E2 plus 1010 colony forming units (CFU) bacterial ghosts (BG) provided complete protection against lethal Classical swine fever virus (CSFV) challenge and the efficacy was comparable to TCID50 rAdV-SFV-E2, which indicates that BG can decrease the effective immunization dose of rAdV-SFV-E2 by at least 10-fold

Read more

Summary

Introduction

Classical swine fever (CSF) is one of the most contagious diseases and characterized by high fever and high mortality, resulting in huge economic losses to the pig industry [1]. Developing a safe and effective marker vaccine allowing differentiation of infected from vaccinated animals (DIVA) is very important. To address this issue, we developed a marker CSF vaccine rAdV-SFV-E2 based on human adenovirus type 5 (HAdV-5)/alphavirus replicon chimeric vector. We demonstrate that rAdV-SFV-E2 can elicit strong cellular and humoral responses in pigs and provide sterile immunity and complete protection against lethal CSFV challenge comparable to the C-strain [6, 7]. From an economic point of view, it is necessary to reduce the minimum effective dose (MED) of the vaccine

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call